Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

Clinical trial NCT06035016 · RECRUITING

Trial details

NCT number: NCT06035016
Sponsor: Peking Union Medical College Hospital
Status: RECRUITING
Study type: OBSERVATIONAL

HER2-positive Breast Cancer Early-stage Breast Cancer

Start date: 2023-06-01
Primary completion: 2027-06-01
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.